Aptose Biosciences (TSE:APS - Get Free Report) NASDAQ: APTO was upgraded by investment analysts at Alliance Global Partners to a "strong-buy" rating in a research report issued on Thursday,Zacks.com reports.
Aptose Biosciences Trading Up 4.7 %
APS traded up C$0.18 during midday trading on Thursday, hitting C$3.99. The company's stock had a trading volume of 1,931 shares, compared to its average volume of 52,210. The firm has a market cap of C$171.80 million, a P/E ratio of -0.79 and a beta of 1.36. Aptose Biosciences has a 52-week low of C$0.16 and a 52-week high of C$5.29. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The firm has a 50-day moving average price of C$8.36 and a two-hundred day moving average price of C$12.04.
About Aptose Biosciences
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
